Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

C ompany  a nnouncement – No. 67 / 202 1

Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical Studies

C ompany a nnouncement – No. 66 / 202 1

Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)

Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity

Company announcement – No. 64  / 202 1

Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021

C ompany a nnouncement – No. 63 / 202 1

Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

C ompany a nnouncement – No. 59 / 202 1

Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models – in Contrast to Short-acting GLP-2

C ompany a nnouncement – No. 57 / 202 1

Zealand Pharma to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

New Employee Elected Director to the board of Zealand Pharma A/S

C ompany a nnouncement – No. 55  / 202 1

Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium

C ompany a nnouncement – No. 52 / 202 1

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Employee Elected Director to step down from the board of Zealand Pharma A/S

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q2 2021 Results - Earnings Call Transcript

Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas

C ompany a nnouncement – No. 49  / 202 1

Zealand Pharma Hosts Conference Call on August 12 at 4 pm CET (10am ET) to Present Second Quarter Results for 2021

C ompany a nnouncement – No. 47  / 202 1

Zealand Pharma A/S – Transaction Under Share Repurchase Program

Company announcement – No.  45 / 202 1

ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

C ompany a nnouncement – No. 43 / 202 1

Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)

Zealand Pharma A/S - Share Buy-Back Program Under Safe Harbour to Aquire Danish Common Stock for Employee Incentive Programs

C ompany a nnouncement – No. 41 / 202 1

Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection

C ompany a nnouncement – No. 40 / 202 1

Zealand Pharma to Participate in LifeSci Nordic Biotech Summit

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

C ompany a nnouncement – No. 36 / 202 1

Zealand Pharma to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH). The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 45690

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Company announcement – No. 33  / 20 2 1

News for Zealand Pharma Stock (ZEAL)